Controlled substances; regulate sale of nonpsychoactive consumable hemp products by Agriculture Department; require sale of products only in pharmacies; add psychoactive derivatives of hemp as Schedule I drug
Impact
This bill will significantly impact state laws by amending existing regulations concerning hemp-derived products and their sale. It sets forth rigorous testing protocols, establishing a seed-to-sale tracking program overseen by the Department of Agriculture and Industries. Moreover, products sold must use hemp cultivated within Alabama, which may promote local agriculture. The implications suggest a higher standard of safety in the market for these products, potentially increasing consumer trust and safety.
Summary
SB1 aims to regulate the sale of nonpsychoactive consumable hemp products and to classify psychoactive derivatives of hemp as controlled substances. The bill mandates that all ingestible hemp products containing nonpsychoactive cannabinoids, such as CBD, be sold only in certified pharmacies. These pharmacies must be certified by the Alabama State Board of Pharmacy and are subject to annual inspections. To ensure quality and safety, all consumable hemp products will be required to undergo laboratory testing before being sold to the public.
Contention
Notable points of contention surrounding SB1 may arise from the bill's strict regulation of consumable hemp products. While proponents view it as necessary for consumer safety and quality control, critics may argue that the strict licensing and testing requirements could limit access to these products. Additionally, there may be concerns about the classification of psychoactive cannabinoids, which could restrict certain hemp-derived products deemed safe by consumers and advocates in the hemp community. Continued debate is expected regarding the balance between regulation and access.